Sign inJoin waitlistJoin the waitlist

Christian Diego Rolfo

Director of the Division of Medical Oncology · OSUCCC – James

Credentials: · · · · ·

History

The Ohio State University College of Medicine
Present

University of Milan
2000–2003
University of Milan
1999
Universidad de Cordoba
1991–1996

Research

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre,…
The Lancet Oncology · 2012 · 4,634 citations
Screening for epidermal growth factor receptor mutations in lung cancer
New England Journal of Medicine · 2009 · 2,004 citations
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology · 2021 · First of 28 authors · 557 citations

Luis Raez
54 papers
Luis Corrales
20 papers · 18 as a resident
David Gandara
16 papers
Katherine Scilla
14 papers · 1 as a fellow
Edgardo Santos
13 papers
Ranee Mehra
10 papers
Aung Naing
9 papers
David Carbone
8 papers
David Hong
8 papers
Massimo Cristofanilli
8 papers
Vivek Subbiah
8 papers
AD
Alexander Drilon
7 papers

Grants

University of Maryland Greenebaum Cancer Centersupport Grant
National Cancer Institute · P30
Project lead · $473.6K · University of Maryland Baltimore
2008–2021
First in Human Phase I/II Clinical Trial of ONC-392: Preserving CTLA-4 Immune Tolerance Checkpoint for Safer and More Effective Cancer Immunotherapy
National Cancer Institute · R44
PI · $400K · oncoc4, Inc.
2020

Clinical trials

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2024–2028
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2024–2028
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2019–2029